DMAC

Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

Scheduled to vest in four equal quarterly installments.

Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

Scheduled to vest in four substantially equal quarterly installments.

Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

Scheduled to vest in four equal quarterly installments.

Scheduled to vest in four equal quarterly installments.

Scheduled to vest in four equal quarterly installments.

Scheduled to vest in four equal quarterly installments.

Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.

Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.

Shares are issuable upon settlement of restricted stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026."

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

Represents the conversion of the exercise price from CAD$ to US$ on the transaction date.

Fully vested.

Represents the conversion of the exercise price from CAD$ to US$ on the transaction date.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

112,500 shares vest on the one-year anniversary of the grant date, and the remaining 337,500 shares vest in twelve equal, or as nearly equal as possible, quarterly installments commencing three months after the one-year anniversary of the grant date; provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.

These shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares.

These shares are held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.

These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares.

Vests in four nearly equal quarterly installments over one year.

Vests in four nearly equal quarterly installments over one year.

Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.

Vests in four nearly equal quarterly installments over one year.

Vests in four nearly equal quarterly installments over one year.

Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.

Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.

Vests in four nearly equal quarterly installments over one year.

Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025.

Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time.

Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025.

This option has fully vested.

Vests in 12 nearly equal quarterly installments over three years.

This option has fully vested.

Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 95,016 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 128,360 voting common shares held by Michael Giuffre individually.

This option has fully vested.